Navigation Links
IOF and ESCEO position on atypical femoral fractures and long-term bisphosphonate use
Date:11/24/2010

Leading experts from the European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the International Osteoporosis Foundation (IOF) have published a timely position paper on the association between subtrochanteric femoral (upper thigh bone) fractures and long-term treatment with bisphosphonates.

Bisphosphonates are the most common drug therapy for osteoporotic fracture prevention, prescribed to millions of people around the world. Concern among doctors and patients has arisen following recent media reports that cite a possible association between unusual and unexpected (atypical) fractures of the upper thigh bone and bisphosphonate use.

The Position Paper examines the evidence and concludes that:

  • Atypical fractures in association with bisphosphonate use are rare, estimated at one per 1,000 patients per year.
  • Small clinical case reports and reviews have reported increased risk of these fractures among bisphosphonate users, but a large register-based study and restrospective analyses of phase III trials of bisphosphonates do not show an increased risk.
  • More epidemiological research and well-designed studies are needed to clearly define and characterize atypical fractures and to learn about other risk factors in patients who have suffered these fractures.
  • Available evidence shows that the well-known benefits of bisphosphonate treatment outweigh the relatively low risk of these rare, atypical fractures.

"The risk versus benefit ratio is clear," stated Professor Ren Rizzoli of the Division of Bone Diseases at the University of Geneva and lead author of the Position Paper. "We estimate that for every 10,000 high-risk patients undergoing bisphosphonate treatment, approximately 100 hip fractures and 750 fractures at other sites are prevented, whereas only 3 to 6 atypical fractures could be expected."

"While we urge patients to discuss their concerns with their doctors, it is important that they do not stop taking their prescribed bisphosphonate therapy and so leave themselves open to the higher risk of osteoporotic fracture." He went on to state that doctors should, as with all drug treatments, advise patients of any potential side effects or risks. Patients with pain in the hips, thighs or femur should be radiologically assessed, and examined for possible atypical subtrochanteric fracture. The radiographic changes should be examined for orthopaedic intervention or close monitoring. The decision regarding therapy should be based on an individual benefit-risk assessment.


'/>"/>

Contact: L. Misteli
info@iofbonehealth.org
41-229-940-100
International Osteoporosis Foundation
Source:Eurekalert

Related biology news :

1. ESCEO-AMGEN Osteoporosis Fellowships awarded in Florence
2. ESCEO-IOF-ABBH Young Investigator Awards recognize research excellence
3. Announcing the 1st IOF-ESCEO Pre-Clinical Symposium
4. Organic soils continue to acidify despite reduction in acidic deposition
5. CACI Awarded a Prime Position on $500 Million, Multiple-Award Program with Biometrics Operations and Support Services
6. Effectiveness of progesterone in reducing preterm births may be altered by genetic predisposition
7. Periodontitis and myocardial infarction: A shared genetic predisposition
8. Tree species composition influences nitrogen loss from forests
9. ADA releases updated position statement on functional foods
10. Rumbaughs theory links positions of Wilson, Skinner
11. Breastfeeding duration and weaning diet may shape childs body composition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/20/2017)... March 20, 2017 At this year,s CeBIT Chancellor ... biometrics manufacturer DERMALOG. The Chancellor came to the DERMALOG stand together with ... this year,s CeBIT partner country. At the largest German biometrics company the ... fingerprint, face and iris recognition as well as DERMALOG´s multi-biometrics system.   ... ...
(Date:3/9/2017)... Australia , March 9, 2017 4Dx ... prestigious World Lung Imaging Workshop at the University of ... was invited to deliver the latest data to world ... recognised event brings together leaders at the forefront of ... in lung imaging. "The quality of ...
(Date:3/6/2017)... Calif. , March 6, 2017 ... and sales technology, today announced Predictive Sales Coach ... for infusing actionable sales intelligence into Salesforce. This ... automatically enable their sales organizations with deep knowledge ... that allow for intelligent engagement. Predictive Sales Coach ...
Breaking Biology News(10 mins):
(Date:3/30/2017)... 2017  Jazz Pharmaceuticals plc (Nasdaq: JAZZ ... agreements with Nippon Shinyaku, Co., Ltd. for Defitelio ® ... daunorubicin liposome injection), or CPX-351, in Japan ... agreements, Nippon Shinyaku will receive exclusive rights to develop ... in return for an upfront payment to ...
(Date:3/29/2017)... ... March 29, 2017 , ... The Crohn’s & Colitis ... inflammatory bowel diseases (IBD), and ReachMD , the nation’s largest medical education ... learners. , The partnership, which launched in the fall of 2016, includes ...
(Date:3/29/2017)... 29, 2017 "Surging application of gesture control ... government are expected to drive the growth of gesture ... recognition market is expected to be worth USD 18.98 ... between 2017 and 2022. The touchless sensing market is ... growing at a CAGR of 17.44% between 2017 and ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... Nerium International Mexico has been approved as an active member of the ... and protection among distributers and consumers in relationship marketing. This professional organization fosters ...
Breaking Biology Technology: